65,437 trials
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
No Condition · Focus is Neural Effects of Mindfulness Training on Attention
Primary: Reaction Times on the Sustained Attention to Response Task. — 380; 407 milliseconds — p=<0.01
Fibromyalgia
Primary: Responder Status Based on Patient Global Impression of Change (PGIC) Score at Visit 5 (Week 13) — 5; 26 participants
Chronic Kidney Disease
Primary: The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels — 93; 57; 12; 45 participants
Atrial Fibrillation
Primary: Maximum QTcF — 461; 427 ms
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 26 participants
Carcinoma, Non-Small-Cell Lung
Primary: Time to Progression — 3.1 Months
Spinal Tumors
Primary: Toxicity — 14; 0; 0; 0 participants
Polycystic Ovarian Syndrome · Infertility
Primary: Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3 — 1; 0; 1; 0 Participants — p=1.000
Breast Neoplasms
Primary: Time to Progression (TTP) - Expert Evaluation Committee Assessment — 13.8; 11.1 months
Erythema Migrans · Post-Lyme Disease Symptoms
Primary: Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days — 30; 27 participants
Hyponatremia
Primary: Change in Sodium Levels — 139.9; 138.1; 138.1; 138.2 mEq/L — p=0.030
Myopia
Primary: Visual Acuity Monocular — 59; 64; 40; 30 eyes
Multiple Sclerosis
Primary: Fatigue Severity Scale — 5.5; 5.5 units on a scale
Rhegmatogenous Retinal Detachment · Toxic Effect of Silicone · Glaucoma Due to Silicon Oil
Primary: Evidence of Retinal Nerve Fibre Layer Thickness Change Measured by Optical Coherence Tomography — 96.23; 87.07; 96.09; 87.93 micrometer